Inventor Search
(search history attached)

=> d ibib abs ind hitstr l11 1-1

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:550873 HCAPLUS
DOCUMENT NUMBER: 141:82339
TITLE: Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum glucose-lowering and serum lipid-lowering activity
INVENTOR(S): Giannessi, Fabio; Tassoni, Emanuela ; Tinti, Maria Ornella; Pessotto, Pompeo; Dell'Uomo, Natalina; Sciarroni, Anna Floriana; Brunetti, Tiziana; Milazzo, Ferdinando Maria
PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056355	A1	20040708	WO 2003-IT820	20031216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506627	AA	20040708	CA 2003-2506627	20031216
AU 2003288546	A1	20040714	AU 2003-288546	20031216
EP 1572180	A1	20050914	EP 2003-780669	20031216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017359	A	20051108	BR 2003-17359	20031216
CN 1728992	A	20060201	CN 2003-80106699	20031216
JP 2006512362	T2	20060413	JP 2004-561981	20031216
PRIORITY APPLN. INFO.:			IT 2002-RM629 A	20021219
			WO 2003-IT820 W	20031216

OTHER SOURCE(S): MARPAT 141:82339
GI



I

AB The invention describes the use of derivs. of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids I [R = H, (un)substituted

(hetero)aryl; n = 0-3; p = 0, 1; X = OH, O-(C1-4 alkyl); R1, R2 = H, C1-5 alkyl, COX; Q = NH, O, S, NHC(O)O, etc.; Y = O, S] for the preparation of a medicament for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidemias. Compound preparation is also described.

IC ICM A61K031-19
ICS C07C053-134; C07C327-16; A61P003-06; A61P003-08; A61P003-10

CC 1-10 (Pharmacology)
Section cross-reference(s): 25

ST phenylthiocarboxylate phenyloxycarboxylate deriv prepn hypoglycemic hypolipidemic; insulin resistance hyperlipidemia treatment phenylthiocarboxylate phenyloxycarboxylate deriv; antidiabetic NIDDM phenylthiocarboxylate phenyloxycarboxylate deriv

IT Antiarteriosclerotics
(antiatherosclerotics; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
(capsules; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
(controlled-release; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Artery, disease
(coronary; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
(depot; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Blood vessel, disease
(diabetic macroangiopathy; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Blood vessel, disease
(diabetic microangiopathy; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Kidney, disease
(diabetic nephropathy; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Nerve, disease
(diabetic neuropathy; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Eye, disease
(diabetic retinopathy; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
(emulsions; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Liver, disease
(fatty; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
(implants; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Heart, disease
(infarction; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
(injections, s.c.; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(injections; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(liposomes; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(liqs.; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Metabolic disorders
(metabolic syndrome X; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Liver, disease
(non-alc. fatty liver disease; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Diabetes mellitus
(non-insulin-dependent; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Hepatitis
(nonalc. steatohepatitis; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(oral; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(parenterals; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Blood vessel, disease
(peripheral; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Anticholesteremic agents
Antidiabetic agents
Antihypertensives
Antiobesity agents
Atherosclerosis
Cardiovascular agents
Diabetes mellitus
Hypercholesterolemia
Hyperglycemia
Hypertension
Hypolipemic agents
Nervous system agents
Obesity
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Glycerides, biological studies
High-density lipoproteins
Hyperlipidemia
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Ovary, disease
(polycystic; phenylthiocarboxylic and phenyloxycarboxylic acid derivs.

with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(powders; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(solids; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(solns.; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Brain, disease
(stroke; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(suspensions; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(syrups; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(tablets, coated; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(tablets; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT 50-99-7, D-Glucose, biological studies 4429-04-3, Fructosamine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT 566189-21-7P 566189-22-8P 566189-23-9P
566189-32-0P 566189-35-3P 566189-36-4P
566189-42-2P 566189-43-3P 566189-44-4P
714912-30-8P 714912-31-9P 714912-32-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT 566189-24-0P 566189-39-7P 566189-41-1P
566189-45-5P 714912-24-0P 714912-25-1P
714912-26-2P 714912-27-3P 714912-28-4P
714912-29-5P 714912-33-1P 714912-34-2P
714912-35-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT 120-72-9, Indole, reactions 540-51-2, 2-Bromoethanol
637-89-8, 4-Mercaptophenol 1484-14-6,
9H-Carbazole-9-ethanol 1485-07-0, 2-(2-Naphthyl)ethanol

1875-88-3, 4-Chlorophenethyl alcohol 2493-04-1,
5-Nitrofurfuryl alcohol 23426-63-3, Methyl 2-bromoisobutyrate
40248-84-8, 3-Mercaptophenol 81156-68-5,
2,4-Dichlorophenethyl alcohol 374818-89-0 714912-36-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT 121459-15-2P, 1-(2-Hydroxyethyl)indole 566189-18-2P
566189-20-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT 12619-70-4D, Cyclodextrin, complexes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT 50-99-7, D-Glucose, biological studies 4429-04-3,
Fructosamine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

RN 50-99-7 HCAPLUS
CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4429-04-3 HCAPLUS
CN D-Fructose, 1-amino-1-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 566189-21-7P 566189-22-8P 566189-23-9P
566189-32-0P 566189-35-3P 566189-36-4P
566189-42-2P 566189-43-3P 566189-44-4P
714912-30-8P 714912-31-9P 714912-32-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum

glucose-lowering and serum lipid-lowering activity)

RN 566189-21-7 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-22-8 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(1H-indol-1-yl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-23-9 HCAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-(2-naphthalenyl)ethoxy]phenyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-32-0 HCAPLUS
CN Propanoic acid, 2-methyl-2-[[3-[2-(2-naphthalenyl)ethoxy]phenyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-35-3 HCAPLUS
CN Propanoic acid, 2-[[3-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-36-4 HCAPLUS
CN Propanoic acid, 2-[[3-[2-(1H-indol-1-yl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-42-2 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-43-3 HCAPLUS
CN Propanoic acid, 2-[[3-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-44-4 HCAPLUS
CN Propanoic acid, 2-[[3-[2-(9H-carbazol-9-yl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 714912-30-8 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(5-methoxy-1H-indol-1-yl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 714912-31-9 HCAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[5-(phenylmethoxy)-1H-indol-1-yl]ethoxy]phenyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 714912-32-0 HCAPLUS
CN Propanoic acid, 2-methyl-2-[[3-[[5-(4-nitrophenyl)-2-furanyl]oxy]phenyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



IT 566189-24-0P 566189-39-7P 566189-41-1P

566189-45-5P 714912-24-0P 714912-25-1P
714912-26-2P 714912-27-3P 714912-28-4P
714912-29-5P 714912-33-1P 714912-34-2P
714912-35-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

RN 566189-24-0 HCAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-(2-naphthalenyl)ethoxy]phenyl]thio]- (9CI) (CA INDEX NAME)



RN 566189-39-7 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 566189-41-1 HCAPLUS
CN Propanoic acid, 2-[[3-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 566189-45-5 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(9H-carbazol-9-yl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 714912-24-0 HCAPLUS
CN Propanoic acid, 2-[[3-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 714912-25-1 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 714912-26-2 HCAPLUS
CN Propanoic acid, 2-[[3-[2-(9H-carbazol-9-yl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 714912-27-3 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(1H-indol-1-yl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 714912-28-4 HCAPLUS
CN Propanoic acid, 2-[[3-[2-(1H-indol-1-yl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 714912-29-5 HCAPLUS
CN Propanoic acid, 2-methyl-2-[[3-[2-(2-naphthalenyl)ethoxy]phenyl]thio]- (9CI) (CA INDEX NAME)



RN 714912-33-1 HCAPLUS

CN Propanoic acid, 2-[[4-[2-(5-methoxy-1H-indol-1-yl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 714912-34-2 HCAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[5-(phenylmethoxy)-1H-indol-1-yl]ethoxy]phenyl]thio]- (9CI) (CA INDEX NAME)



RN 714912-35-3 HCAPLUS
CN Propanoic acid, 2-methyl-2-[[3-[[5-(4-nitrophenyl)-2-furanyl]oxy]phenyl]thio]- (9CI) (CA INDEX NAME)



IT 120-72-9, Indole, reactions 540-51-2, 2-Bromoethanol 637-89-8, 4-Mercaptophenol 1484-14-6, 9H-Carbazole-9-ethanol 1485-07-0, 2-(2-Naphthyl)ethanol 1875-88-3, 4-Chlorophenethyl alcohol 2493-04-1, 5-Nitrofurfuryl alcohol 23426-63-3, Methyl 2-bromoisobutyrate 40248-84-8, 3-Mercaptophenol 81156-68-5, 2,4-Dichlorophenethyl alcohol 374818-89-0 714912-36-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
RN 120-72-9 HCAPLUS
CN 1H-Indole (9CI) (CA INDEX NAME)



RN 540-51-2 HCAPLUS

CN Ethanol, 2-bromo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 637-89-8 HCAPLUS
CN Phenol, 4-mercapto- (9CI) (CA INDEX NAME)



RN 1484-14-6 HCAPLUS
CN 9H-Carbazole-9-ethanol (9CI) (CA INDEX NAME)



RN 1485-07-0 HCAPLUS
CN 2-Naphthaleneethanol (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 1875-88-3 HCAPLUS
CN Benzeneethanol, 4-chloro- (9CI) (CA INDEX NAME)



RN 2493-04-1 HCAPLUS
CN 2-Furanmethanol, 5-nitro- (9CI) (CA INDEX NAME)



RN 23426-63-3 HCAPLUS
CN Propanoic acid, 2-bromo-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 40248-84-8 HCAPLUS
CN Phenol, 3-mercapto- (9CI) (CA INDEX NAME)



RN 81156-68-5 HCAPLUS
CN Benzeneethanol, 2,4-dichloro- (9CI) (CA INDEX NAME)



RN 374818-89-0 HCAPLUS
CN 1H-Indole-1-ethanol, 5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 714912-36-4 HCAPLUS
CN 1H-Indole-1-ethanol, 5-methoxy- (9CI) (CA INDEX NAME)



IT 121459-15-2P, 1-(2-Hydroxyethyl)indole 566189-18-2P
566189-20-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
RN 121459-15-2 HCAPLUS

CN 1H-Indole-1-ethanol (9CI) (CA INDEX NAME)



RN 566189-18-2 HCAPLUS
CN Propanoic acid, 2-[(4-hydroxyphenyl)thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-20-6 HCAPLUS
CN Propanoic acid, 2-[(3-hydroxyphenyl)thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



IT 12619-70-4D, Cyclodextrin, complexes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
RN 12619-70-4 HCAPLUS
CN Cyclodextrin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 15:33:15 ON 11 JUL 2006)

     FILE 'HCAPLUS' ENTERED AT 15:33:32 ON 11 JUL 2006
                E GIANNESSI FABIO/AU
L1           54 S E2-3
                E TASSONI EMANUELA/AU
L2           24 S E2-3
                E TINTI MARIA ORNELLA/AU
L3           94 S E2-4
                E PESSOTTO POMPEO/AU
L4           16 S E2-3
                E DELLUOMO NATALINA/AU
                E DELL UOMO NATALINA/AU
L5           14 S E3
                E SCIARRONI ANNA FLORIANA/AU
L6            9 S E2-4
                E BRUNETTI TIZIANA/AU
L7            6 S E2-3
                E MILAZZO FERDINANDO MARIA/AU
L8            5 S E1-3
L9            2 S L1 AND L2 AND L3 AND L4 AND L5 AND L6 AND L7 AND L8
                SELECT RN L9 2

     FILE 'REGISTRY' ENTERED AT 15:36:01 ON 11 JUL 2006
L10          44 S E1-44

     FILE 'HCAPLUS' ENTERED AT 15:36:16 ON 11 JUL 2006
L11           1 S L9 AND L10
L12          ANALYZE L11 1-1 CT :      30 TERMS
```

=> d

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 566189-21-7 REGISTRY
ED Entered STN: 14 Aug 2003
CN Propanoic acid, 2-[[4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H21 Cl O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 14 Aug 2003

=> d ibib abs hitstr l8 1-2

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:550873 HCAPLUS
DOCUMENT NUMBER: 141:82339
TITLE: Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum glucose-lowering and serum lipid-lowering activity
INVENTOR(S): Giannessi, Fabio; Tassoni, Emanuela; Tinti, Maria Ornella; Pessotto, Pompeo; Dell'Uomo, Natalina; Sciarroni, Anna Floriana; Brunetti, Tiziana; Milazzo, Ferdinando Maria
PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056355	A1	20040708	WO 2003-IT820	20031216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506627	AA	20040708	CA 2003-2506627	20031216
AU 2003288546	A1	20040714	AU 2003-288546	20031216
EP 1572180	A1	20050914	EP 2003-780669	20031216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017359	A	20051108	BR 2003-17359	20031216
CN 1728992	A	20060201	CN 2003-80106699	20031216
JP 2006512362	T2	20060413	JP 2004-561981	20031216
US 2006154979	A1	20060713	US 2005-539833	20050719

PRIORITY APPLN. INFO.: IT 2002-RM629 A 20021219
WO 2003-IT820 W 20031216

OTHER SOURCE(S): MARPAT 141:82339
GI



I

AB The invention describes the use of derivs. of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids I [R = H, (un)substituted

(hetero)aryl; n = 0-3; p = 0, 1; X = OH, O-(C1-4 alkyl); R1, R2 = H, C1-5 alkyl, COX; Q = NH, O, S, NHC(O)O, etc.; Y = O, S] for the preparation of a medicament for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidemias. Compound preparation is also described.

IT 566189-21-7P 566189-42-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

RN 566189-21-7 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-42-2 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



IT 566189-39-7P 714912-25-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

RN 566189-39-7 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 714912-25-1 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio]-2-methyl-

(9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:570951 HCAPLUS
DOCUMENT NUMBER: 139:133346
TITLE: Preparation of derivatives of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids useful for the treatment of diseases responding to PPARα activation
INVENTOR(S): Giannessi, Fabio; Dell'Uomo, Natalina; Tassoni, Emanuela; Tinti, Maria Ornella; Sciarroni, Anna Floriana; Bandera, Monica; Pessotto, Pompeo; Arduini, Arduino
PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059875	A2	20030724	WO 2003-IT11	20030115
WO 2003059875	A3	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472223	AA	20030724	CA 2003-2472223	20030115
AU 2003209679	A1	20030730	AU 2003-209679	20030115
EP 1474387	A2	20041110	EP 2003-729547	20030115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003006824	A	20041221	BR 2003-6824	20030115
JP 2005514456	T2	20050519	JP 2003-559979	20030115
CN 1620429	A	20050525	CN 2003-802289	20030115
US 2005054671	A1	20050310	US 2004-501472	20041110
PRIORITY APPLN. INFO.:			IT 2002-RM14 A	20020115

WO 2003-IT11 W 20030115

OTHER SOURCE(S): MARPAT 139:133346

GI



I

AB Title compds. I [R = H, YCR5R6COX, mono- bi- tricyclic (hetero)aryl; m = 0-1; n = 0-3; when n = 1, R3-4 = H, alkyl, when n = 2-3, R3 = R4 = H; p = 0-1; X = OH, alkoxy; R1-2, R5-6 = H, alkyl, alkoxy, acyl, etc.; Q, Z = NH, O, S, amido, etc.; Y = O, S] are prepared For instance, 4-mercaptophenol is reacted with Me α-bromoisobutyrate (CH3CN, NaH) to give Me 2-(4-hydroxyphenylthio)isobutyrate. Selected compds. exhibit PPARα agonist activity at 2μM. I are useful for the treatment of heart failure, the hyperlipemias and atherosclerosis.

IT 566189-21-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of derivs. of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids as PPARα agonists)

RN 566189-21-7 HCAPLUS

CN Propanoic acid, 2-[[4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



IT 566189-39-7P, 2-[[4-[2-(4-Chlorophenyl)ethoxy]phenyl]thio]-2-methylpropanoic acid 566189-42-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of derivs. of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids as PPARα agonists)

RN 566189-39-7 HCAPLUS

CN Propanoic acid, 2-[[4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 566189-42-2 HCAPLUS
CN Propanoic acid, 2-[[4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



=> d que stat l8
L5 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L7 4 SEA FILE=REGISTRY SSS FUL L5
L8 2 SEA FILE=HCAPLUS ABB=ON L7

```
=> d his ful

     (FILE 'HOME' ENTERED AT 14:24:55 ON 17 JUL 2006)

     FILE 'REGISTRY' ENTERED AT 14:25:11 ON 17 JUL 2006
L1             STRUCTURE 566189-21-7
L2           0 SEA SSS SAM L1
L3           0 SEA SSS SAM L1
L4           1 SEA ABB=ON  566189-21-7/RN
               D
L5             STRUCTURE 566189-21-7
L6           0 SEA SSS SAM L5
L7           4 SEA SSS FUL L5
               D SCAN

     FILE 'HCAPLUS' ENTERED AT 14:33:00 ON 17 JUL 2006
L8           2 SEA ABB=ON  L7
               D AU 1-2
               D IBIB ABS HITSTR L8 1-2
               D QUE STAT L8


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   14 JUL 2006  HIGHEST RN 892755-86-1
     DICTIONARY FILE UPDATES:  14 JUL 2006  HIGHEST RN 892755-86-1

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 17 Jul 2006  VOL 145 ISS 4
     FILE LAST UPDATED: 16 Jul 2006  (20060716/ED)
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.